Clinical Trial Update: Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating axicabtagene ciloleucel versus standard-of-care therapy as first-line treatment for high-risk diffuse large B-cell lymphoma. The s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Axicabtagene ciloleucel (axicabtagene ciloleucel)

Snippet

Sponsor: Kite, A Gilead Company | Conditions: High-risk Large B-cell Lymphoma (LBCL) | Phase 3 | Status: ACTIVE_NOT_RECRUITING